Genmab achieves $3 million milestone payment in DuoBody(r) collaboration with Janssen COPENHAGEN, Denmark, Oct. 25, 2015 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today it has achieved a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. ("Janssen"), triggering a $3 million milestone payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Janssen has optioned 11 programs out of a total of 20 programs under the bispecific DuoBody platform collaboration with Genmab. Including the collaboration with Janssen, Genmab has five commercial partnerships for its DuoBody technology....
↧
